Global Outsourcing Conference Report

Over the last three days we've been taking part and presenting at the third Global Outsourcing Conference, jointly organized by Xavier University and the US FDA.

Although not the best attended of conferences this year, it proved to be one of the best in terms of content presented and the quality of the invited speakers, including a couple of key note addresses from senior members of US FDA. This resulted in some very interesting and beneficial discussions amongst the attendees, all of whom have taken home some thought provoking material and ideas for implementing positive change in terms of better securing the supply chain, assuring product and patient safety and in optimizing the performance of their extended enterprises.

The conference looked at a wide range of outsourcing and supply chain issues, ranging from the pragmatic management of outsourcing and supply chain management best practices, with a mixture of practical best practices from the pharmaceutical industry and research and experience from a number of leading Universities working in the field (presentations are currently available on the Xavier GOC website).

Of significant interest were the FDA presentations looking at the implications of the recent FDA Safety and Innovation Act (FDASIA - due to be signed into law next month) and the changes that this will have in terms of changes to GMP and GDP regulations.

There was a significant interest in the topic of serialization and ePedigree - which was covered in a number of sessions and signs are that companies are now realizing that rolling these solutions out will be necessary and more difficult than originally envisaged when compared to simpler pilot studies.

Supplier selection, assessment and management were also key topics with the focus on developing partnerships and relationships as the best way of meeting forthcoming regulatory expectations for the management of suppliers.

Business & Decision presented a deep dive session on the future challenges faced by ERP System and Process Owners, looking at the need to integrate with serialization systems, master data management systems, and supply chain partners systems. Acknowledging that many ERP systems were never designed to handle such a level of integration, the session looked at how middleware solutions such as Business Process Management solutions and SOA can be used to better integrate the supply chain.

Outsourcing clearly isn't going away and although some companies are looking to in-source some strategic products and services once again, the issues associated with outsourcing cannot be ignored. Although examples from India and China were much in evidence it was also acknowledged that outsourcing risks do not solely exist in so-called 'emerging economies'

This issues exist not only with product (API, excipients and other starting materials), but also with services such as IT services and it is clear that the US FDA expect companies to better manage their suppliers and supply chain.

For pharmaceutical companies looking to get involved in the debate there is the opportunity to follow the discussion on-line in the LinkedIn "Xavier Pharmaceutical Community".

In summary, the conference provided pharmaceutical companies with a comprehensive list of the topics they will need to be address in the next 1 - 3 years, which now need to be developed into a road map leading to on-going compliance, improved product and patient safety and more efficient and cost-effective supply chain operations.

What’s in a (Unique) Number?

Over the past eighteen months I’ve been contributing to a hefty tome which focuses on supply chain management in the pharmaceutical sector, specifically looking at some of the regulatory issues associated with information systems and information technology.

Amongst the issues I identified as still requiring resolution was the need to be able to more effectively track products through the automated supply chain in order to counter the growing problems of counterfeiting, to reduce dispensing errors and to better support product recalls.
The good news is that in the time it has taken to write, review, edit and publish a book there has been significant progress by various industry bodies and regulators in defining what is needed in terms of:

• Uniquely identifying product at multiple levels, down to the final package or device,
• Establishing databases to share information and reduce duplication of data
• Leveraging existing standards such as GS1 Healthcare Standards

This not only includes drug products but also medical devices and while there is still a way to go with respect to international harmonization the increasing adoption or incorporation of standards such as GS1 means that it should be possible for manufacturers to develop internal identification codes that can be used internationally in the commercial supply chain and also meet the various requirements of different regulatory bodies.

While there is still a long way to go with respect to tackling specific issues such as how to label a re-usable, sterilizable medical device or how to label combination products it seems as if solutions are within the grasp of the industry – a fact borne out by the number of large pharmaceutical and medical device companies now investing considerable sums of money in developing solutions.

Regulators are accepting that any regulations should be indepedent of any specific technology and that sensible exceptions (or alternatives) may be required for specific product profiles or devices.

However, to truly develop and deliver workable and cost effective solutions it is necessary to look beyond the basic information technology that assigns and registers identification numbers, prints and scans and compiles data bases.

Much of the discussion is currently being driven by technology vendors who have admittedly gone a long way to making such solutions possible. However, there appear to be very few technology vendors who are looking at the big picture. It also appears that individual pharmaceutical and medical device companies focus upon specific aspects of the full end-to-end solution, depending on the specific experience and ‘hot buttons’ of the teams looking at these solutions. While some teams focus on how to use RFID others are concerned about how relabeling should be managed, but I've seen relatively few companies putting everything together to deliver not just regulatory compliance, but real business advantage.

While information technology will of course underpin any serialization, track ‘n’ trace or electronic pedigree solution it is information systems that will deliver efficient and cost effective solutions.

This requires that Regulated Companies look beyond the printers, laser etching, label stock, etc and take a look at the strategic information flows and business processes that will be needed to make these technologies work as a business solution.

This requires a strategic review of:

• Product master data management, at multiple levels and across all geographies - addressing the critical issues of consistent product codes and the federation and synchronisation of products codes between systems,
• Serial number allocation, management and security on a global basis - remembering that real time solutions will need to work even while the Internet connection to some central database is down,
• Changes to packaging and labelling operations, which may restrict the flexibility that some organizations are used to - it will no longer be possible to assemble-to-order or label in country unless unique serial numbers can be generated at the right point in the supply chain,
• Modifications to business processes to support serialisation - including necessary changes to supporting transactional applications such as MES, ERP and CRM systems,
• Integration of systems ranging from printing, labelling and scanning systems at the bottom end, through MES and into ERP systems at the top end – and the realignment of the supported business processes,
• Collaborative working with third parties including contract manufacturers, customers and regulators – ensuring that identification data is available to trusted and authenticated users while assuring the security of individual serial numbers. 

These key business challenges need to be addressed while at the same time tackling the necessary information technology challenges. As even small pilots have discovered, relying on people to populate this data is extremely time consuming and inefficient - in many cases we're talking about maintaining tens of thousands of product codes and serial numbers into the hundreds of millions. To work properly solutions will need to rely upon internet services and service oriented architecture (SOA) – and area where the Life Sciences industry has been lagging behind other industries.
With regulatory deadlines (e.g.now looming in the US and Europe Life Sciences organizations are now starting to address the issue seriously – but let’s just hope that it isn’t too late. While it is certainly possible to implement partial solutions in time to meet key regulatory milestones unless these issues are tackled at a strategic business level the cost to industry may well outweigh the benefit in terms of risk mitigation.

Labeling and Identification in Life Sciences – A Perfect Storm?

At least a couple of times today I heard the various regulations currently being drafted around the area of product labeling and identification as a ‘Perfect Storm’, driving Life Sciences companies to address these issues.

While Pedigree requirements have been deferred in the US, the US FDA continues to make progress with their UDI initiative that would require unique product identification for medical devices, at least to the level currently required for ethical drugs (requiring the National Drug Code, expiry date and batch number to be included in human and machine readable format) and blood products (where the international ISBT 128 standard is required).

At the same time, the European Union is slowly making progress on the issue of serialization, which is of course already a requirement in many countries for some classes of medical device.

While individual software solutions can help in these areas (see below), the implications of these requirements on Life Sciences companies may be enormous. While many Regulated Companies are seeing this as solely as an IT issue, the reality it is that in some cases complying with these regulations will require significant changes to supply chain models and significant investments in terms of upgrading facilities or even setting up complete new packaging, labeling and distribution centers.

While the business issues are enormous at least some of the software vendors are taking the issue seriously. Here at Oracle OpenWorld there are numerous vendors with labeling and printing solutions, but the most significant news from Oracle is the pending availability of their Oracle Pedigree and Serialization Manager (OPSM), which is set to be at the heart of many serialization and labeling solutions.

OPSM provides the ability to generate and manage serial numbers, interface to ERP and labeling/packaging systems and the ability to submit secure serial numbers to the proposed Government databases . Even better, OPSM is significantly ‘software service’ enabled which means that it is relatively easy to integrate with external systems (it is one of Oracle’s first ‘Fusion Applications’, having been developed on Oracle’s open standards based Fusion Middleware), with the majority of transactions running in the background (generating, tracking and submitting serial numbers, maintaining a database of packaging hierarchies etc).

The use of integrated Fusion Middleware based Business Intelligence means that users in the Life Sciences industry will be able to focus on exceptions (suspect serial numbers, potential counterfeited product, matching and authorizing returns etc) without having to manually interchange data between systems. While other serialization products exist, OPSM has the potential to be at the center of serialization business processes in pharmaceuticals and medical devices, uniquely integrating ERP systems, shop floor packaging and labeling systems and submission to the coming Government databases.

Based on the traffic at the OPSM stand in the OpenWorld exhibition hall there appears to be a good deal of interest in the product - there is certainly a need given current and pending regulations in this area. It will be interesting to see how many Regulated Companies really understand the nature of the coming “Perfect Storm” and translate their interest in OPSM in to real world solutions.